JLE

Epileptic Disorders

MENU

Antiepileptic drugs: indications other than epilepsy Volume 6, numéro 2, June 2004

1. Beghi E. The use of anticonvulsants in neurological conditions other than epilepsy: a review of the evidence from randomized controlled trials. CNS Drugs 1999; 11: 61-82.

2. Cheshire WP. Trigeminal neuralgia: a guide to drug choice. CNS Drugs 1997; 7: 98-110.

3. Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin J Pain 2002; 18: 22-7.

4. Beghi E. Carbamazepine: clinical efficacy and use in other neurologic disorders. In: Levy RH, Matson RH, Meldrum BS, Perucca E eds. Antiepileptic Drugs, 5th ed. Lippincott Williams, Wilkins, Philadelphia, 2002; 273-7.

5. Blom S. Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G-32883). Lancet 1962; I: 829-40.

6. Rockliff BW, Davis EH. Controlled sequential trials of carbamazepine in trigeminal neuralgia. Arch Neurol 1966; 15: 129-36.

7. Campbell FG, Graham JG, Zilkha KJ. Clinical trial of carbamazepine (Tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiat 1966; 29: 265-7.

8. Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia. Arch Neurol 1968; 19: 129-36.

9. Nicol CF. A four year double blind study of Tegretol in facial pain. Headache 1969; 9: 54-7.

10. Vilming ST, Lyberg T, Lataste X. Tizanidine in the management of trigeminal neuralgia. Cephalalgia 1986; 6: 181-2.

11. Lindstrom P, Lindblom U. The analgesic effect of tocainide in trigeminal neuralgia. Pain 1987; 28: 45-50.

12. Leichin F, van der Dijs B, Lechin ME. Pimozide therapy for trigeminal neuralgia. Arch Neurol 1989; 46: 960-3.

13. Tomson T, Tybring G, Bertilsson L, et al. Carbamazepine therapy in trigeminal neuralgia: clinical effects in relation to plasma concentration. Arch Neurol 1980; 37: 699-703.

14. Tomson T, Bertilsson L. Potent therapeutic effect of carbamazepine-10,11-epoxide in trigeminal neuralgia. Arch Neurol 1984; 41: 588-601.

15. Peiris JB, Perera GLS, Devendra SV, et al. Sodium valproate in trigeminal neuralgia. Med J Aust 1980; 2: 278.

16. Desai N, Shah K, Gandhi I. Baclofen sodium valproate combination in carbamazepine resistant trigeminal neuralgia: a double blind clinical trial. Cephalalgia 1991; 11 (Suppl. 11): 321-2.

17. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, et al. Lamotrigine (Lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain 1997; 73: 223-30.

18. Khan OA. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology 1998; 51: 611-4.

19. Zvartau-Hind M, Din MU, Gilani A, et al. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology 2000; 55: 1587-88.

20. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: mechanism of action and place in therapy. Drugs 2000; 60: 1029-52.

21. Backonja MM. Use of anticonvulsants for treatment of neuropathic pain. Neurology 2002; 59 (5 Suppl. 2): S14-7.

22. Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain 2002; 6 (Suppl. A): 61-8.

23. Rull JA, Quibrera R, Gonzalez-Millan H, et al. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine: double-blind crossover study. Diabetologia 1969; 5: 215-20.

24. Gomez-Perez FJ, Choza R, Rios M, et al. Nortriptyline-fluphenazine versus carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch Med Res 1996; 27: 525-9.

25. Gerson GR. Studies on the concomitant use of carbamazepine and clomipramine for the relief of post-herpetic neuralgia. Postgrad Med J 1977; 53 (Suppl. 4): 104-9.

26. Keczkes K, Basheer AM. Do corticosteroids prevent post-herpetic neuralgia ? Br J Dermatol 1980; 102: 551-5.

27. Leijon G, Boivie J. Central post-stroke pain: a controlled trial of amitriptyline and carbamazepine. Pain 1989; 36: 27-36.

28. Tripathi M, Kaushik S. Carbamazepine for pain management in Guillain-Barrè syndrome patients in the intensive care unit. Crit Care Med 2000; 28: 655-8.

29. Swerdlow M. Anticonvulsant drugs and chronic pain. Clin Neuropharmacol 1984; 7: 51-82.

30. Saudek CD, Werns S, Reidenberg MM. Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther 1977; 22: 196-9.

31. Chadda VS, Mathur MS. Double-blind study of the effects of diphenhylhydantoin sodium on diabetic neuropathy. J Assoc Physicians India 1978; 26: 403-6.

32. Lockman LA, Hunningghake DB, Krivit W, et al. Relief of pain of Fabry’s disease by diphenhylhydantoin. Neurology 1973; 23: 871-5.

33. McCleane GJ. Intravenous infusion of phenytoin relieves neuropathic pain: a randomized, double-blinded, placebo-controlled, crossover study. Anesth Analg 1999; 89: 985-8.

34. Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002; 57: 451-62.

35. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain; evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003; 25: 81-104.

36. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831-6.

37. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837-42.

38. Morello CM, Leckband SG, Stoner CP, et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999; 159: 1931-7.

39. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo-controlled study. Pain 2001; 94: 215-24.

40. Serpell MG. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain 2002; 99: 557-66.

41. Tai Q, Kirshblum S, Chen B, et al. Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. J Spinal Cord Med 2002; 25: 100-5.

42. Pandey CK, Bose N, Garg G, et al. Gabapentin for the treatment of pain in Guillain-Barrè syndrome: a double-blinded, placebo-controlled, crossover study. Anesth Analg 2002; 95: 1719-23.

43. Bone M, Critchley P, Buggy DJ. Gabapentin in postamputation phantom limb pain; a randomized, double-blind, placebo-controlled, cross-over study. Reg Anesth Pain Med 2002; 27: 481-6.

44. Dirks J, Fredensborg BB, Christensen D, et al. A randomized study of the effects of single-dose gabapentin versus placebo on postoperative pain and morphine consumption after mastectomy. Anesthesiology 2002; 97: 560-4.

45. Simpson DM, Olney R, McArthur JC, et al. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 2000; 54: 2115-9.

46. Vestergaard K, Andersen G, Gottrup H, et al. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 2001; 56: 184-90.

47. McCleane G. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomised, double-blind, placebo controlled trial. Pain 1999; 83: 105-7.

48. Kamin M. Topiramate: clinical efficacy and use in nonepileptic disorders. In: Levy RH, Matson RH, Meldrum BS, Perucca E eds. Antiepileptic Drugs, 5th ed. Lippincott Williams, Wilkins, Philadelphia, 2002; 753-9.

49. Dworkin RH, Corbin AE, Young JP, et al. Pregabalin for the treatment of postherpetic neuralgia; a randomized, placebo-controlled trial. Neurology 2003; 60: 1274-83.

50. Krymchantowski AV, Bigal ME, Moreira PF. New and emerging prophylactic agents for migraine. CNS Drugs 2002; 16: 611-34.

51. Silberstein SD. Valproic acid: clinical efficacy and use in other neurological disorders. In: Levy RH, Matson RH, Meldrum BS, Perucca E eds. Antiepileptic Drugs, 5th ed. Lippincott Williams, Wilkins, Philadelphia, 2002; 818-27.

52. Hering R, Kuritzki A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992; 12: 81-4.

53. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994; 44: 647-51.

54. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995; 52: 281-6.

55. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled-study. Cephalalgia 1997; 17: 103-8.

56. Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 1995; 54: 1141-5.

57. Silberstein SD, Collins SD. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term Safety of Depakote in Headache Prophylaxis Study Group. Headache 1999; 39: 633-43.

58. Edwards KR, Glantz MJ, Shea P, et al. Topiramate for migraine prophylaxis: a double-blind, randomized, placebo-controlled study. Headache 2000; 40: 407.

59. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001; 41: 968-75.

60. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41: 119-28.

61. Lampl C, Buzath A, Klinger D, Neuman K. Lamotrigine in the prophylactic treatment of migraine aura: a pilot study. Cephalalgia 1999; 19: 58-63.

62. D’Andrea G, Granella F, Cadaldini M, Manzoni GC. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 1999; 19: 64-6.

63. Steiner TJ, Findley LJ, Yuen AWC. Lamotrigine vs placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997; 17: 109-12.

64. Pathwa R, Lyons KE. Essential tremor: differential diagnosis and current therapy. Am J Med 2003; 115: 134-42.

65. Koller WC, Hristova A, Brin M. Pharmacological treatment of essential tremor. Neurology 2000; 54 (11 Suppl 4): S30-8.

66. Gorman WP, Cooper R, Pocock P, et al. A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis. J Neurol Neurosurg Psychiatry 1986; 49: 64-8.

67. Pathwa R, Lyons K, Hubble JP, et al. Double-blind controlled trial of gabapentin in essential tremor. Mov Disord 1998; 13: 465-7.

68. Gironell A, Kulisevsky J, Barbanoj M, et al. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol 1999; 56: 475-80.

69. Connor GS. A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology 2002; 59: 132-4.

70. Post RM, Tasman A, Goldfinger SM, et al. Alternatives to lithium for bipolar affective illness. Review of Psychiatry. Washington, American Psychiatric Press, vol. 9, 1990: 170-202.

71. Post RM, Leverich GS, Pazzaglia PJ, et al. Lithium tolerance and discontinuation as pathways to refractoriness. Brich NJ, Padgham C, Hughes MS (eds.), Lithium in medicine and biology, 1st ed., vol.#8. Lanchashire, Marius Press, 1993.

72. Ballenger J, Post RM. Therapeutic effects of carbamazepine in affective illness: a preliminary report. Commun Psychopharmacol 1978; 2: 159-75.

73. Okuma T, Inanaga K, Otsuki S, et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology 1979; 66: 211-7.

74. Grossi E, Sacchetti E, Vita A. Carbamazepine vs. chlorpromazine in mania: a double-blind trial. In: Emrich HM, Okuma T, Muller AA (eds): Anticonvulsants in Affective Disorders. Amsterdam. Excerpta Medica 1984: 177-87.

75. Post RM, Berettini W, Uhde TW, et al. Selective response to the anticonvulsant carbamazepine in manic depressive illness: a case study. J Clin Psychopharmacol 1984; 4: 178-85.

76. Lenzi A, Lazzerini E, Massimetti G, et al. Use of carbamazepine in acute psychosis: a controlled study. J Int Med Res 1986; 14: 78-84.

77. Brown D, Silverstone T, Cookson J. Carbamazepine compared to haloperidol in acute mania. Int J Clin Psychopharmacol 1987; 48: 89-93.

78. Lerer B, Moore N, Meyendorff E, et al. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987; 48: 89-93.

79. Lusznat RM, Murphy DP, Nunn CMH. Carbamazepine vs. lithium in the treatment of prophylaxis of mania. Br J Psychiatry 1988; 153: 198-204.

80. Moller MJ, Kissling W, Riehl T, et al. Double-blind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 127-36.

81. Okuma T, Yamashita I, Takahashi R, et al. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry 1990; 23: 143-50.

82. Small JG. Anticonvulsant in affective disorders. Psychopharmacol Bull 1990; 26: 25-36.

83. Small JG, Kappler MH, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991; 48: 915-21.

84. Keck PE Jr, McElroy SL, Nemeroff CB. Anticonvulsants in the treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci 1992; 4: 395-405.

85. Dunn RT, Frye MS, Kimbrell TA, et al. The efficacy and use of anticonvulsants in mood disorders. Clin Neuropharmacol 1998; 21: 215-35.

86. Neumann J, Seidel K, Wunderlich HP. Comparative studies of the effect of carbamazepine and trimipramine in depression. In: Emrich HM, Okuma T, Muller AA (eds): Anticonvulsants in Affective Disorders. Amsterdam. Excerpta Medica 1984: 160-6.

87. Post RM, Uhde TW, Roy-Byrne PP, et al. Antidepressant effects of carbamazepine. Am J Psychiatry 1986; 143: 29-34.

88. Okuma T, Inan aga K, Otsuki S, et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology 1981; 73: 95-6.

89. Placidi GF, Lenzi A, Lazzerini F, et al. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry 1986; 47: 490-4.

90. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992; 85: 114-8.

91. Simhandl C, Denk E, Thau K. The comparative efficacy of carbamazepine low and high serum level and lithium carbonate in the prophylaxis of affective disorders. J Affect Disord 1993; 28: 221-31.

92. Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders: a randomised study. J Affect Disord 1997; 43: 151-61.

93. Post RM, Leverich GS, Rosoff AS, et al. Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up. J Clin Psychopharmacol 1990; 10: 318-27.

94. Kishimoto A, Ogura C, Hazama H, et al. Long term prophylaptic effects of carbamazepine in affective disorder. Br J Psychiatry 1983; 143: 327-31.

95. Post RM, Uhde TW, Roy-Byrne PP, et al. Correlates of antimanic response to carbamazepine. Psychiatry 1987; 21: 71-83.

96. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Valproate in bipolar disorder: literature review and treatment guidelines. J Clin Psychopharmacol 1992; 12: 42S-52S.

97. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271: 918-24.

98. Brennan MJW, Sandyk R, Borsook D. Use of sodium valproate in the management of affective disorders: basic and clinical aspects. In: Emrich HM, Okuma T, Muller AA (eds): Anticonvulsants in Affective Disorders. Amsterdam. Excerpta Medica 1984: 56-65.

99. Emrich HM, Dose M, von Zerssen D. The use of sodium valproate, carbamazepine, and oxcarbazepine in patients with affective disorders. J Affect Disord 1985; 8: 243-50.

100. Freeman TW, Clothier JL, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992; 149: 108-11.

101. Pope HG Jr, McElroy SL, Keck PE Jr, et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991; 48: 62-8.

102. Keck PE Jr, McElroy SL, Tugrul KC, et al. Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 1993, 54: 305-8.

103. Sachs GS, Altshuler L, Ketter TA, et al. Divalproex versus placebo for the treatment of bipolar depression. Presented at the ACNP Annual Meeting, Puerto Rico, December 2001.

104. Young LT, Joffe RT, Robb JC, et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000; 157: 124-6.

105. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57: 481-9.

106. Lambert PA, Venaud G. Comparative study of valpromide versus lithium in treatment of affective disorders. Nervure 1992; 5: 57-65.

107. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Correlates of antimanic response to valproate. Psychopharmacol Bull 1991; 27: 127-33.

108. Calabrese JR, Bowden CL, McElroy SL, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999; 156: 1019-23.

109. Bowden CL. Lamotrigine in the treatment of bipolar disorder. Expert Opin Pharmacother 2002; 3: 1513-19.

110. Calabrese JC, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled lamotrigine monotherapy in outpatients with Bipolar I Depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60: 79-88.

111. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61: 841-50.

112. Frye M, Ketter T, Kimbrell TA, et al. A placebo controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607-14.

113. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400.

114. Emrich HM, Dose M, von Zerssen D. The use of sodium valproate, carbamazepine, and oxcarbazepine in patients with affective disorders. J Affect Disord 1985; 8: 243-50.

115. Muller AA, Stoll KD. Carbamazepine and oxcarbamazepine in in the treatment of manic syndromes: studies in Germany. In: Emrich HM, Okuma T, Muller AA (eds): Anticonvulsants in Affective Disorders. Amsterdam. Excerpta Medica 1984: 139-47.

116. Emrich HM. Studies with oxcarbazepine in acute mania. Int Clin Psychopharmacol 1990; 5: 83-8.

117. Cabrera JF, Muhlbauer HD, Schley J. Long-term randomized clinical trial of oxcarbazepine vs lithium in bipolar and schizoaffective disorders: preliminary results. Pharmacopsychiatry 1986; 19: 282-3.

118. Wildegrube C. Case studies on prophylactic long-terms effects of oxcarbazepine in recurrent affective disorders. Int Clin Psychopharmacol 1990; 5: 89-94.

119. Perugi G, Toni C, Frare F, et al. Oxcarbazepine in patients with bipolar disorder resistant or intolerant to standard mood stabilizers: an open case series. Neuropsychobiology, in press.

120. Carta MG, Hardoy MC, Hardoy MJ, et al. The clinical use of gabapentin in bipolar spectrum disorders. J Affect Disord 2003; 75: 83-91.

121. Perugi G, Akiskal HS. The soft bipolar spectrum redefined: Focus on the anxious-sensitive, impulse-discontrol and binge-eating connection in bipolar II and related conditions. Psychiatr Clin N Am 2002; 4: 713-37.

122. Altshuler LL, Keck PE, Mc Elroy SL, et al. Gabapentin in the treatment of refractory bipolar disorders. Bipolar Disorder 1999; 1: 342-54.

123. Perugi G, Toni C, Ruffolo G, Sartini S, Simonini E, Akiskal H. Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states. Pharmacopsychiatry 1999; 32:136-41.

124. Sokolski KN, Green C, Maris DE, DeMet EM. Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology. Ann Clin Psychiatry 1999, 11: 217-22.

125. Schaffer CB, Schaffer LC. Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment. J Affect Disord 1999; 55: 237-40.

126. Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Disord 2000; 2: 249-55.

127. Ghaemi SN, Katzof JJ, Desai SP, Goodwin FK. Gabapentin treatment of mood disorders: a preliminary study. J Clin Psychiatry 1998; 59: 426-29.

128. Crockatt J, Greiner M, Clift L, Pande A. Treatment of panic disorder with gabapentin. 38th Annual Meeting, New Clinical Drug Evaluation Unit Program, Boca Raton, Florida 1998.

129. Pande AC, Davidson J, Jefferson J. Treatment of social phobia with gabapentin: a placebo controlled study. J Clin Psychopharmacol 1999; 19: 341-8.

130. Perugi G, Toni C, Frare F, et al. Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity ? J Clin Psychopharmacol 2002; 22: 584-91.

131. Young LT, Robb JC, Patelis Siotis I, et al. Acute treatment of bipolar depression with gabapentin. Biol Psychiatry 1997; 42: 851-3.

132. Maurer I, Volz HP, Saurer H. Gabapentin leads to remission of somatoform pain disorder with major depression. Pharmacopsychiatry 1999; 32: 255-7.

133. Suppes T. Review of the use of topiramate for treatment of bipolar disorders. J Clin Psychopharmacol 2002; 22: 599-609.

134. Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 1998; 50: 245-51.

135. Chengappa KN, Rathore D, Levine J, et al. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord 1999; 1: 42-53.

136. McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000; 47: 1025-33.

137. Grunze HC, Normann C, Langosch J, et al. Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. J Clin Psychiatry 2001; 62: 464-8.

138. Calabrese JR, Keck PE, McElroy SL, et al. A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Psychopharmacol 2001; 21: 340-2.

139. Ghaemi SN, Manwani SG, Katzow JJ, et al. Topiramate treatment of bipolar spectrum disorders: a retrospective chart review. Ann Clin Psychiatry 2001, 13: 185-9.

140. Guille C, Sachs G. Clinical outcome of adjunctive topiramate treatment in a sample of refractory bipolar patients with comorbid conditions. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1035-9.

141. McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002; 4: 207-13.

142. Grunze H, Erfurth A, Marcuse A, et al. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999; 60: 759-62.

143. Schaffer LC, Schaffer CB, Howe J. An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients. J Affect Disord 2002; 71: 259-63.

144. Suppes T, Chisholm KA, Dhavale D, et al. Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord 2002; 4: 283-9.

145. Kamba S, Yagi G, Kamijima K, et al. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsicopharmacol Biol Psychiatry 1994, 18: 707-15.

146. Post RM, Denicoff KD, Frye MA, et al. A history of the use of anticonvulsivants as mood stabilizers in the last two decades of the 20th century. Neuropsychobiology 1998; 38: 152-66.

147. Ghaemi SN, Gaughan S. Novel anticonvulsants: a new generation of mood stabilizers. Harv Rev Psychiatry 2000; 8: 1-7.

148. Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 1996; 42: 531-43.